Cytotoxicity of cisplatin in bladder cancer is significantly enhanced by application of bcl-2 antisense oligonucleotides
Background: The aim of our study was to examine the effects of the combined application of cisplatin and bcl-2 antisense oligonucleotide on human bladder cancer cell lines to determine the possible synergistic effects in cytotoxicity and to estimate its potential value for subsequent in vivo trials....
Gespeichert in:
| Hauptverfasser: | , , , , , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
20 July 2004
|
| In: |
Urologic oncology
Year: 2004, Jahrgang: 22, Heft: 3, Pages: 188-192 |
| ISSN: | 1873-2496 |
| DOI: | 10.1016/j.urolonc.2004.01.010 |
| Online-Zugang: | Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1016/j.urolonc.2004.01.010 Verlag, lizenzpflichtig, Volltext: https://www.sciencedirect.com/science/article/pii/S1078143904000328 
|
| Verfasserangaben: | Axel Schaaf, Sreedhar Sagi, Sigrun Langbein, M.D., Lutz Trojan, M.D., Peter Alken, M.D., Maurice Stephan Michel, M.D. |
| Zusammenfassung: | Background: The aim of our study was to examine the effects of the combined application of cisplatin and bcl-2 antisense oligonucleotide on human bladder cancer cell lines to determine the possible synergistic effects in cytotoxicity and to estimate its potential value for subsequent in vivo trials. Materials and methods: Human bladder cancer cell lines (UM-UC 3, RT 112, T24/83 and HT 1197) were treated with bcl-2 antisense oligonucleotide, cisplatin, or a combination of both and incubated for 48 h under standard conditions. Cell survival was determined using a Neubauer haemocytometer or standard MTT assay. BCL-2 expression was verified using western blotting. Results: The combined treatment resulted in significant lower cell survival rates compared to individual treatment. Additionally, there was a decrease in cell survival rate with an increase in cisplatin concentration in combined treatment that was not observed in cisplatin mono treatment. Conclusions: For the combined treatment with oligonucleotides and cisplatin a synergistic effect can be strongly suggested. Therefore, further investigations and in vivo trials have to be done to determine the possible benefits for clinical applications. |
|---|---|
| Beschreibung: | Gesehen am 07.03.2022 |
| Beschreibung: | Online Resource |
| ISSN: | 1873-2496 |
| DOI: | 10.1016/j.urolonc.2004.01.010 |